Other formats:
BibTeX
LaTeX
RIS
@article{1528856,
author = {Bělohlávková, Petra and Steinerová, Kateřina and Karas, Michal and Skoumalová, Ivana and Rohoň, Peter and Indrák, Karel and Voglová, Jaroslava and Vrbacký, Filip and Cmunt, Eduard and Nečasová, Tereza and Křístková, Zlatuše and Trněný, Marek and Žák, Pavel and Papajík, Tomáš and Faber, Edgar},
article_location = {OXFORD},
article_number = {JUN 2019},
doi = {http://dx.doi.org/10.1016/j.leukres.2019.04.011},
keywords = {Age; Chronic myeloid leukaemia; Imatinib; Treatment; Dosage},
language = {eng},
issn = {0145-2126},
journal = {Leukemia Research},
title = {First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter},
url = {http://www.sciencedirect.com/science/article/pii/S014521261930075X},
volume = {81},
year = {2019}
}
TY - JOUR
ID - 1528856
AU - Bělohlávková, Petra - Steinerová, Kateřina - Karas, Michal - Skoumalová, Ivana - Rohoň, Peter - Indrák, Karel - Voglová, Jaroslava - Vrbacký, Filip - Cmunt, Eduard - Nečasová, Tereza - Křístková, Zlatuše - Trněný, Marek - Žák, Pavel - Papajík, Tomáš - Faber, Edgar
PY - 2019
TI - First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter
JF - Leukemia Research
VL - 81
IS - JUN 2019
SP - 67-74
EP - 67-74
PB - PERGAMON-ELSEVIER SCIENCE LTD
SN - 01452126
KW - Age
KW - Chronic myeloid leukaemia
KW - Imatinib
KW - Treatment
KW - Dosage
UR - http://www.sciencedirect.com/science/article/pii/S014521261930075X
L2 - http://www.sciencedirect.com/science/article/pii/S014521261930075X
N2 - We retrospectively evaluated the role of age and dosage in 372 CML patients (170 women, 202 men) treated with first-line imatinib (IMA) from the records of the CAMELIA registry. The median follow-up of the patients was 82.3 (18.0-177.3) months. The treatment results of 80 elderly patients aged over 65 years at diagnosis were compared in analysis "A" with those of 292 younger patients and in analysis " B" with those of 90 patients younger than 40 and 202 patients aged 40-64. The elderly patients had statistically adverse values of the Sokal, ELTS, and ECOG scores and Charlson comorbidity index in both analyses (p from= 0.012 to <= 0.001). Despite a more frequent use of a daily dose lower than 400 mg - in 31 elderly patients (38.8%) than in 45 younger ones (15.4%) (p < 0.001), there were no statistically significant differences in the achievement of optimal haematological, cytogenetic, and molecular responses according to the ELN criteria in both the analyses, A and B. The comparisons of overall survival with CML-related death (OSCML) and event-free survival (EFS) were insignificant inanalysis A (p = 0.07 and 0.396, respectively) but progression-free survival (PFS) differed significantly (p = 0.007). In analysis B OSCML and PFS differed significantly (p = 0.027 and 0.003) but EFS was similar (p = 0.351). Elderly patients with a sustained dose of IMA of 400 mg/day have insignificantly better OS, PFS, and EFS compared to patients treated with a lower dosage of IMA. The results in the treatment of the elderly CML patients were comparable with those of the younger ones in terms of the probabilities of the achievement of optimal ELN responses. However, the results for the survival probabilities were influenced by age and the IMA dosage.
ER -
BĚLOHLÁVKOVÁ, Petra, Kateřina STEINEROVÁ, Michal KARAS, Ivana SKOUMALOVÁ, Peter ROHOŇ, Karel INDRÁK, Jaroslava VOGLOVÁ, Filip VRBACKÝ, Eduard CMUNT, Tereza NEČASOVÁ, Zlatuše KŘÍSTKOVÁ, Marek TRNĚNÝ, Pavel ŽÁK, Tomáš PAPAJÍK and Edgar FABER. First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter. \textit{Leukemia Research}. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2019, vol.~81, JUN 2019, p.~67-74. ISSN~0145-2126. Available from: https://dx.doi.org/10.1016/j.leukres.2019.04.011.
|
